Zigakibart is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in IgA Nephropathy (Berger’s Disease). According to Globaldata, it is involved in 5 clinical trials, of which 1 was completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Zigakibart’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zigakibart is expected to reach an annual total of $89 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zigakibart Overview
Zigakibart is under development for the treatment of IgA nephropathy. It comprises of humanized IgG4 monoclonal antibody. The drug candidate targets APRIL-dependent survival in B-cell malignancies. The drug candidate is developed based on B-select antibody platform (B-select) technology. It is administered by intravenous and subcutaneous route. It was also under development for the treatment of B-cell chronic lymphocytic lymphoma, colorectal cancer and relapsed or refractory multiple myeloma.
See Also:
Novartis Overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Zigakibart’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.